Birt-Hogg-Dubé (BHD) syndrome is an inherited kidney cancer syndrome that is characterized by benign hair follicle tumors, lung cysts, spontaneous pneumothorax, and an increased risk of renal neoplasia ( 1 -3 ) . We previously identified germline mutations in the BHD gene, which is located at chromosome 17p11.2, in BHD patients ( 4 ) . Nearly all BHD mutations are frameshift or nonsense mutations that are predicted to prematurely truncate the BHD protein, folliculin (FLCN) ( 4 -7 ) . BHD patients most frequently develop bilateral multifocal chromophobe renal tumors and renal oncocytic hybrid tumors with features of chromophobe renal carcinoma and renal oncocytoma ( 8 -10 ) . Somatic mutations in the remaining wild-type copy of BHD and loss of heterozygosity at chromosome 17p11. 2 
Methods
We used recombineering methods to generate mice with a conditional BHD allele and introduced the cadherin 16 (KSP) -Cre transgene to target BHD inactivation to the kidney. Kidney cell proliferation was measured by BrdU incorporation and phospho-histone H3 staining. Kidney weight data were analyzed with Wilcoxon ' s rank-sum, Student's t , and Welch's t tests. Hematoxylin and eosin staining and immunoblot analysis and immunohistochemistry of cell cycle and signaling proteins were performed on mouse kidney cells and tissues. BHD knockout mice and kidney cells isolated from BHD knockout and control mice were treated with the mTOR inhibitor rapamycin. Mouse survival was evaluated by Kaplan-Meier analyses. All statistical tests were two-sided.
Results
BHD knockout mice developed enlarged polycystic kidneys and died from renal failure by 3 weeks of age. Targeted BHD knockout led to the activation of Raf-extracellular signal-regulated protein kinase (Erk)1/2 and Akt-mTOR pathways in the kidneys and increased expression of cell cycle proteins and cell proliferation. Rapamycin-treated BHD knockout mice had smaller kidneys than buffer-treated BHD knockout mice had (n = 4 -6 mice per group, relative kidney/body weight ratios, mean = 4.64% vs 12.2%, difference = 7.6%, 95% confidence interval = 5.2% to 10.0%; P < .001) and longer median survival time (n = 4 -5 mice per group, 41.5 vs 23 days; P = .0065 ).
) cassette, flanked by Frt and loxP sequences, was inserted into intron 6 of BHD for positive selection, and the thymidine kinase gene was included for negative selection. A second loxP sequence was inserted into intron 7. The targeting vector was electroporated into mouse embryonic stem cells, which were selected for G418 resistance and gancyclovir sensitivity. Correctly targeted embryonic stem cells were identified by Southern blot analysis and injected into mouse blastocysts to produce chimeras. Backcrossing to C57BL/6 mice produced heterozygous F1 offspring with germline transmission of the BHD floxed (f) allele. The retained Neo cassette flanked by Frt sites was excised in vivo by crossing the heterozygous BHD floxed (BHD f/+ ) F1 mice with mice expressing the Flp recombinase transgene under the ubiquitous ␤ -actin promoter to produce BHD f/+ /Flp mice. Subsequently, the Flp transgene was removed from the BHD f/+ /Flp mice by backcrossing to C57BL/6 mice to produce BHD f/+ mice. BHD f/f mice were generated by intercrossing BHD f/+ mice. To produce the BHD deleted (d) allele, BHD f/+ mice were crossed with mice expressing the Cre recombinase transgene under the ␤ -actin promoter, resulting in BHD d/+ / ␤ -actin Cre mice ( 24 ) . The ␤ -actin Cre transgene was removed from the BHD d/+ / ␤ -actin Cre mice by backcrossing to C57BL/6 mice, resulting in BHD d/+ mice. Deletion of exon 7 in the BHD d/+ mice resulted in a frameshift and premature termination codon in exon 8. KSP-Cre transgenic mice (n = 4), which expressed Cre recombinase under the cadherin 16 promoter specifically in the adult renal tubules and developing genitourinary tract ( 22 ) , were crossed with BHD d/+ mice (n = 6) to generate BHD d/+ /KSP-Cre mice (n = 39). To produce mice with kidney-specific inactivation of BHD, BHD d/+ /KSPCre male mice (n = 10) were mated with BHD f/f female mice (n = 13). Littermates with the BHD f/d /KSP-Cre genotype (n = 89) and BHD f/+ /KSP-Cre genotype (n = 84) were killed by CO 2 asphyxiation or decapitation and analyzed for phenotype at day (P) 2, P7, P14, and P21.
To verify that BHD knockout was targeted to the kidney and to visualize Cre expression, we developed BHD
CONTEXT AND CAVEATS

Prior knowledge
Patients with Birt-Hogg-Dubé (BHD) syndrome who carry inactivating mutations in both copies of the BHD tumor suppressor gene have an increased risk for kidney cancer. Folliculin, the protein encoded by the BHD gene, may interact with the 5'AMP-activated protein kinase-mammalian target of rapamycin (AMPK-mTOR) signaling pathway, a key regulator of cell growth and proliferation.
Study design
Kidney-targeted BHD knockout mouse model to examine how loss of BHD affects kidney function, the potential pathways involved, and therapies that target those pathways.
Contribution
BHD knockout mice died from renal failure and had enlarged cystic kidneys due to hyperproliferation and activation of the Erk1/2 and mTOR pathways. Treatment with the mTOR inhibitor rapamycin reduced kidney size and prolonged survival.
Implications
Loss of both copies of the BHD gene may lead to renal tumorigenesis in the mouse. The model used in this study may also be useful to determine the mechanisms of kidney carcinogenesis.
Limitations
The mouse model used in this study may not precisely recapitulate BHD syndrome in humans; additional genetic changes may be required for progression to kidney carcinogenesis.
Downloaded from https://academic.oup.com/jnci/article-abstract/100/2/140/1130264 by guest on 27 February 2019 mice . BHD f/f mice were crossed with Rosa26lacZ mice (obtained from Philippe Soriano, Fred Hutchinson Cancer Research Center, Seattle) to produce BHD f/+ /Rosa26lacZ mice (n = 10). BHD f/+ /Rosa26lacZ mice (n = 6) were intercrossed to produce BHD f/f /Rosa26lacZ mice (n = 5). BHD f/f /Rosa26lacZ female mice (n = 2) were crossed with BHD d/+ /KSP-Cre male mice (n = 2) to generate BHD
Antibodies
The following antibodies were used: horseradish peroxidase -labeled goat anti-mouse IgG, goat anti-rabbit IgG, rabbit polyclonal cyclin A, rabbit monoclonal cdc2, and rabbit polyclonal vacuolar-H + ATPase (Santa Cruz Biotechnology, Santa Cruz, CA); acetylated tubulin (Sigma, St Louis, MO); rabbit polyclonal Na-K-Cl cotransporter 2 (NKCC2) (Chemicon, Temecula, CA); rabbit polyclonal thiazide-sensitive Na-Cl cotransporter (TSC, gift from Mark Knepper); lectin Dolichos biflorus agglutinin (DBA) and lectin Lotus tetragonolobus agglutinin (LTA) (Vector Laboratories, Burlingame, CA ); rabbit monoclonal phospho-S6 ribosomal protein (S6R), rabbit monoclonal S6R, rabbit polyclonal phospho-AKT, rabbit polyclonal AKT, rabbit monoclonal phospho-AMPK ␣ , rabbit polyclonal AMPK ␣ 1, rabbit monoclonal cyclin D1, rabbit monoclonal phospho-c-Raf, rabbit polyclonal phospho-MEK1/2, rabbit polyclonal phospho-Erk1/2, rabbit polyclonal phospho-p90RSK, rabbit polyclonal phospho-mTOR, and rabbit polyclonal mTOR (Cell Signaling, Danvers, MA); rabbit polyclonal actin (Biomedical Technology, Stoughton, MA); mouse monoclonal BrdU (DAKO, Carpinteria, CA); rabbit polyclonal phospho-histoneH3 (Upstate, Charlottesville, VA); rabbit polyclonal cdk4 (Clontech, Mountain View, CA); and rabbit polyclonal cyclin B1 [( 25 ) gift from Philipp Kaldis]. FLCN-105, a rabbit polyclonal antibody against GST -FLCN, and FLCN-mAb in culture medium from single clone hybridoma cell line raised against full-length GST-FLCN in the mouse were prepared as described previously ( 12 ) .
Immunoblot Analysis of Folliculin and Quantitative
Reverse Transcription-Polymerase Chain Reaction Expression Analysis of the BHD Gene Three-week-old mice were killed by CO 2 asphyxiation (n = 3 each genotype), and their kidneys were removed, cut into small pieces, snap frozen in liquid nitrogen, and stored at -80°C until further analysis. For each mouse, one frozen kidney piece was homogenized in radioimmunoprecipitation assay buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM Na 3 VO 4 , 50 mM NaF, 1.0% Triton X-100, 0.5% deoxycholate, 0.1% sodium dodecylsulfate [SDS], 100 nM calyculin A, and Complete Protease Inhibitor cocktail [Roche, Molecular Biochemicals, Indianapolis, IN]) with a Polytron homogenizer on ice followed by centrifugation at 16 000 × g for 30 minutes. Protein concentrations of cleared supernatants were measured with the BCA Protein Assay Kit (Pierce, IL) and adjusted to 1.33 mg/mL, 4× SDS-sample buffer was added, and samples were boiled for 5 minutes to produce 1 mg/mL sample lysates. A total of 20 µ g of protein was subjected to 4% -20% or 4% -15% SDS-polyacrylamide gel electrophoresis. Immunoblotting was performed as previously described ( 12 ) . Antibodies were diluted as follows: mouse monoclonal FLCN, 1 : 1000; ␤ -actin, 1 : 500; cyclin D1, 1 : 1000; cyclin A, 1 : 1000; cyclin B1, 1 : 1000; cdc2, 1 : 1000; CDK4, 1 : 1000; phospho-c-Raf(Ser338), 1 : 1000; phospho-MEK1/ 2(Ser217/221), 1 : 1000; phospho-Erk1/2(Thr201/Tyr204), 1 : 1000; phospho-p90RSK(Ser380), 1 : 1000; phospho-Akt(Thr308), 1 : 1000; Akt, 1 : 1000; phospho-mTOR(Ser2448), 1 : 1000; mTOR, 1 : 1000; phospho-S6R(Ser240/244), 1 : 1000; S6R, 1 : 1000; phospho-AMPK ␣ , 1 : 500. At least three independent experiments were performed with two replicates each . Secondary antibodies were diluted as follows: goat anti-mouse IgG-horseradish peroxidase, 1:1000; goat anti-rabbit IgG-horseradish peroxidase, 1:1000 (Santa Cruz Biotechnology, SantaCruz, CA). Antibody-protein complexes were detected using ECL Western Blotting Detection Reagent (Amersham, Buckinghamshire, UK) according to the manufacturer's instructions.
Total RNA was isolated from frozen kidney tissues (one sample per kidney, one kidney sample per mouse ) using Trizol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. Quantitative reverse transcription (qRT)-PCR was performed as previously described ( 26 ) . The following PCR primers to amplify ␤ -actin and BHD exons 6 and 7 were gen erated by using Primer 3 software:
Three independent experiments were performed in triplicate using the ␤ -actin gene as an internal control. /KSP-Cre mice (n = 70) were weighed, killed by CO 2 asphyxiation (for P14 and P21) or decapitation (for P0, P1, and P7), and dissected. Kidneys were removed, weighed, fixed in 10% neutral-buffered formalin for 24 hours, and subjected to fixation in 70% ethanol. Kidneys were then routinely processed, embedded in paraffin, sectioned at 5 µ m and stained with hematoxylin and eosin (H&E). /KSP-Cre mice (n = 6) were minced into small pieces and dried by vacuum centrifugation at 50°C overnight.
Magnetic Resonance Imaging to Examine
Blood Urea Nitrogen Analyses to Measure Kidney Function
Blood was collected into a Microvette CB300 (Sarstedt, Germany) from decapitated P0, P2, and P7 BHD f/+ /KSP-Cre and BHD f/d /KSPCre mice. P14 and P21 mice were killed by CO 2 asphyxiation, and a cut was made in the right atrium. Blood was collected by pipet, transferred into a Microvette CB300, and centrifuged at 10 000 × g for 5 minutes at 20°C. Serum was collected and stored at Ϫ 80°C for further analysis. Serum samples were placed on a Vitros blood urea nitrogen (BUN)/urea slide, and BUN measurements were performed on a Vitros 250 instrument according to the manufacturer's protocol (Ortho-Clinical Diagnostics, Rochester, NY). /KSP-Cre mice at P7 were randomly divided into two groups for buffer (n = 11) and rapamycin (n = 10) treatment. Rapamycin (LC Laboratories, MA) was dissolved in 100% ethanol at a stock concentration of 10 mg/mL. Rapamycin stock solution was diluted to 200 µ g/mL in buffer (5% Tween 80, 5% PEG400) and injected intraperitoneally at a dose of 2 mg/kg daily. At day 21 or before, if moribund (usually day 19 or 20), mice were killed, kidneys were dissected, kidney/body weight ratios were measured, and histopathology was performed as described above.
Rapamycin Treatment of BHD
For survival analysis, BHD
/KSP-Cre mice at P7 were randomly divided into two groups for buffer (n = 5) and rapamycin (n = 4) treatment. Rapamycin (2 mg/kg per day) or buffer was injected daily intraperitoneally until mice were found dead or moribund. /KSP-Cre mouse were euthanized at P21 and perfused with Liver Perfusion Medium (Invitrogen) and Liver Digest Medium (Invitrogen). After perfusion, kidneys were removed using aseptic technique, minced into small pieces with a razor blade, and incubated in Liver Digest Medium on a rocker at 37°C for 20 -45 minutes. Digested tissues were dissociated by gentle pipetting, washed with Hepatocyte Wash Medium (Invitrogen), and incubated with Accutase (Innovative Cell Technologies, Inc., San Diego, CA) on a rocker at 37°C for 15 minutes. Dissociated tissues were filtered through a 40-µ m cell strainer (BD Biosciences, San Jose, CA) twice, washed with Hepatocyte Wash Medium, resuspended in PBS/0.02% EDTA, and separated by Percoll gradient centrifugation to isolate the tubule cell fraction that fractionated between the PBS and 41.9% Percoll/1X MEM layers. Isolated tubule cell fractions were washed three times with SFFD Medium (Dulbecco's Modified Eagle's Medium, Ham's F-12 [1 : 1], 10 mM Hepes, 1.1 mg/mL sodium bicarbonate, 10 nM sodium selenium) and plated on collagen-I -coated dishes (BD Biosciences) in 10% fetal bovine serum / SFFD medium. After 24 hours, dishes were washed twice with PBS, and medium was replaced with K1 Medium (SFFD medium with 5 µ g/mL insulin, 25 ng/mL PGE1, 5 pM triiodothyronine [T3], 50 nM hydrocortisone, and 5 µ g/mL apo-transferrin). Cells were detached from culture dishes by washing with PBS/0.02% EDTA followed by incubation at 37°C for 15 minutes with Accutase. For cell growth assays, 1 × 10 4 cells were plated on 3.5-cm collagen-I -coated dishes with K1 medium containing 10 nM rapamycin or DMSO diluent as control. Cells were detached from three dishes for each group at each time point by incubation with Accutase and counted using a hemocytometer with two replicates.
Renal Tubule Cell Primary Culture
Immunohistochemistry and Immunofluorescence Analysis of Cell Cycle Markers and Akt-mTOR and Erk-MEK 1/2 Pathway Signaling
Sections (5 µ m) from formalin-fixed, paraffin-embedded tissues were placed on slides for immunohistochemistry. Phospho-histone H3 staining was performed using the Ventana automated immunohistochemistry system (Ventana HX system Dyscovery/20: 750-DSC, Ventana Medical systems, Inc., Tucson, AZ). Antigen retrieval was performed by microwave-heated incubation in citrate buffer for 20 minutes, followed by incubation with rabbit polyclonal anti -phospho-histone H3 (1 : 5000) overnight at 4°C. For immunofluorescence staining, the renal capsules were removed from the kidneys of P0, P2, and P7 mice (n = 3 at each age) in ice-cold PBS, and kidneys were fixed in 4% paraformaldehyde (PFA) for 1.5 hours at 4°C, followed by sucrose replacement (5% -20% sucrose/0.1M sodium phosphate, pH 7.2). Kidneys were then embedded in Optimal Cutting Temperature (OCT) compound, frozen on a metal block in liquid nitrogen, and stored at Ϫ 80°C. P14 and P21 mice (n = 3 at each age) were killed and perfusion fixed with 4% PFA. Kidneys were removed, further fixed in 4% PFA for 1 hour at 4°C, subjected to sucrose replacement, embedded in OCT compound, and frozen as above. Frozen sections (5 µ m) were prepared (n = 20 per mouse), mounted on slides, fixed in methanol/acetone (1 : 1) at Ϫ 20°C for 10 minutes, and blocked with 10% normal goat serum. The slides were then rinsed with PBS, quenched in 0.5 M ammonium chloride/0.1% bovine serum albumin (BSA) in PBS for 15 minutes at room temperature, washed with PBS, and incubated with the primary antibody in buffer containing 10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.01% (v/v) Tween 20, 3% goat serum, and 0.1% (w/v) BSA at 4°C overnight. Antibodies and dilutions were as follows: DBA, 1 : 400; NKCC2, 1 : 1000; LTA, 1 : 400; TSC, 1 : 400; vacuolar H + -ATPase, 1 : 200; cyclin D1, 1 : 50; P-Erk1/2, 1 : 100; P-Akt, 1 : 100; P-mTOR, 1 : 100; P-S6R, 1 : 100. After three 10-minute washes with Tris-buffered saline/Tween 20 (TBST) (10 mM TrisHCl, pH 7.5, 150 mM NaCl, 0.01% [v/v] Tween 20), slides were incubated with Alexa Fluor 488 goat anti-rabbit IgG (1 : 500 dilution) and/or Alexa Fluor 594 goat anti-mouse IgG (1 : 500 dilution) (Invitrogen). After another three 10-minute washes with TBST, slides were sealed with mounting medium containing 4 ′ -6-Diamidino-2-phenylindole (Vector Laboratories) and viewed with a confocal microscope system (LSM 510; Carl Zeiss, Thornwood, NY).
Kidney tumor tissue (n = 16; 10 tumors from patient 1, three tumors from patient 2, two tumors from patient 3, and one tumor from patient 4) and normal kidney parenchyma (n = 4; two normal tissues from patient 2 and one each normal tissues from patients 3 and 4) samples from BHD patients who had been surgically treated at the Urologic Oncology Branch, National Institutes of Health (NIH), Bethesda, MD (with patient permission under an NIH Institutional Review Board -approved protocol #97-C-0147) were frozen in OCT compound without fi xation. Frozen sections were fi xed in methanol/acetone (1 : 1) at Ϫ 20°C for 10 minutes followed by staining with phospho-mTOR antibody using the procedure above.
For cell proliferation measurements, BrdU (100 µ g/g body weight) was injected intraperitoneally into P14 BHD f/+ /KSP-Cre (n = 2) and BHD f/d /KSP-Cre (n = 2) mice, and, 2 hours later, the mice were killed by CO 2 asphyxiation. Kidneys were fi xed with 10% formalin for 24 hours, followed by fi xation in 70% ethanol. Sections that were 5 µ m in thickness (n = 4) were immunostained with mouse monoclonal anti-BrdU antibody (1 : 500) after trypsin pretreatment for 3 hours at 37°C using the ARK kit (DAKO). The number of BrdU-stained cells per 1000 cells in each fi eld was counted in fi ve randomly selected fi elds. ␤ -galactosidase activity was measured in situ in frozen sections (n = 2 per mouse) prepared as described above using standard staining techniques. Tissue sections were counterstained with nuclear fast red (Sigma).
Statistical Analysis
Data were analyzed using both parametric and nonparametric methods and graphical techniques. Kidney weight data were analyzed with Wilcoxon's rank-sum test, Student's t test, and Welch's t test to account for unequal within-group variances. Cell count and longitudinal growth data were analyzed with regression analysis, analysis of variance, and analysis of covariance following logarithmic (base 10) transformation of the data to satisfy the homogeneity of variance assumptions underlying the models. Where appropriate, results are reported or plotted with 95% confidence intervals (CIs). Mouse survival time was defined as the time from birth until the animals died or became moribund. Survival data were estimated and plotted with the Kaplan-Meier method; differences between survival groups were assessed with the logrank test. Statistical analyses were performed with S-Plus (version 7.0, Insightful Corporation, Seattle, WA) and SAS (version 9.1, Cary, NC). All statistical tests were two-sided. P values less than .05 were considered to be statistically significant.
Results
We determined that homozygous BHD deletion is embryonic lethal in the mouse because no BHD d/d offspring were produced from intercrosses of BHD d/+ mice (data not shown). To circumvent embryonic lethality, we developed a conditional BHD knockout mouse. The targeting vector, with loxP sites flanking exon 7 of the BHD gene, was generated by recombineering methodology ( 27 ) ( Fig. 1, A ) . Correctly targeted embryonic stem cell clones were selected by Southern blot screening ( Fig. 1, B ) and used to generate chimeric mice that were then backcrossed to C57BL/6 mice for germline transmission of the BHD floxed (f) allele .
To target BHD deletion to the kidney specifi cally, we used Cre transgenic mice expressing Cre recombinase under the KSP-cadherin (cadherin 16) promoter, which drives Cre expression exclusively in kidney tubule epithelial cells and in the developing genitourinary tract ( 22 ) . BHD /KSP-Cre parents. Mice with kidney-specifi c inactivation of BHD appeared normal at birth but showed distended abdomens by 2 weeks, which were very pronounced at the time of death, at approximately 3 weeks of age. At autopsy, the enlarged kidneys completely fi lled the abdominal cavity, and this phenotype was 100% penetrant in BHD f/d /KSP-Cre mice ( Fig. 2, A ) . MRI with gadolinium enhancement revealed highly cystic features and a fi ne reticular pattern of interstitial tissue containing numerous blood vessels in the BHD-inactivated kidneys ( Fig. 2, B ) , which were not seen in control kidneys (data not shown). BHD mRNA expression levels (relative to internal ␤-actin controls as measured by qRT-PCR) in BHDinactivated kidneys ( Fig. 2, D ) were statistically signifi cantly lower than those of control kidneys (BHD /KSP-Cre littermates revealed no differences at birth or postnatal day (P)2. By 1 week, BHD-inactivated kidneys began to enlarge due to dilation of collecting ducts and some cortical tubules. At 2 weeks, lumens of ducts and tubules were cystic, causing further gross enlargement of the kidneys. At 3 weeks, the kidneys were markedly cystic, the anatomic distinction between cortex and medulla was disrupted, and regions of pyramidal infarctions were observed ( Fig. 2, F ) . We calculated the relative ratio of kidney to body weight in BHD-inactivated mice and control littermates. No statistically signifi cant differences were seen at P2. However, the kidney to body weight ratio in BHD f/d /KSP-Cre mice increased dramatically between P7 and P21 and was statistically signifi cantly One representative image of 40 mice for each genotype is shown. D ) BHD mRNA expression in kidneys of 3-week-old mice as quantifi ed by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) using exon 6 and 7 amplifi cation. Three mice of each genotype were analyzed. Data are presented as means and 95% confi dence intervals (CIs) from three independent experiments, each performed in triplicate (Welch's t test, two-sided,* P < .001). E ) Folliculin (FLCN) expression in control and knockout kidneys was estimated by immunoblot analysis. One representative of three independent experiments performed in two mice is shown. F ) Comparison of BHD control and knockout kidney histology (hematoxylin and eosin staining) at different ages shows no obvious differences at days 0 and 2. At 1 week, BHD knockout mice have enlarged kidneys with dilated collecting ducts and a few dilated cortical tubules. By 2 weeks, most collecting ducts in the medulla are markedly dilated. The entire BHD knockout kidney is diffusely fi lled with cystic collecting ducts and tubules by 3 weeks, and the anatomic distinction between cortex and medulla is lost. One representative of at least three mice at each age is shown. G ) Relative ratio of kidney to body weight (BW; 100% × kidney weight/[BW -kidney weight]) was calculated at different ages. Data are shown as means and 95% confidence intervals (* P = .002, ** P < .001, two-sided, Welch's t test). H ) Relative ratio of dried kidney to body weight (100% × dried kidney weight/[BW -wet kidney weight]) of 3-week-old mice was calculated. Data are represented as means and 95% confi dence intervals (* P < .001, two-sided, Welch's t test). I ) BHD f/d /KSP-Cre mice die of renal failure. Blood urea nitrogen (BUN) levels were determined at different ages. Data are represented as means and 95% confi dence intervals (* P = .03, ** P = .0012, two-sided, Welch's t test). J ) Kaplan-Meier survival analysis shows a statistically signifi cant difference between control and BHD knockout mice for overall survival (two-sided logrank test, P < .001). Median survival time of BHD knockout mice is 21.5 days (n = 24). Dotted lines , 95% confi dence intervals.
greater than that in littermate controls (at P21, mean ratio of kidney to body weight in BHD f/d /KSP -Cre vs BHD f/+ /KSP-Cre mice , 13.1% vs 0.77%, difference = 12.3%, 95% CI = 11.1% to 13.6%; Fig. 2 , C and G ). To adjust for the weight of the fl uid in the dilated tubules and ducts, kidneys from 3-week-old mice were completely dehydrated and reweighed ( Fig. 2, H ) . The ratio of dried kidney to body weight was also greater in BHD knockout mice than in control littermates (BHD f/d /KSP-Cre vs BHD f/+ /KSP-Cre: mean = 1.16% vs 0.21%, difference = 0.95%, 95% CI = 0.84% to 1.06%; P < .001 ).
To evaluate renal function in mice with BHD-inactivated kidneys, BUN levels were measured at different ages and compared with those of littermate controls ( Fig. 2, I ). BUN levels, like kidney to body weight ratios, showed no differences at birth or P2 and only slight changes at 1 week, and were statistically signifi cantly elevated at 2 weeks ( P = .03) and 3 weeks ( P = .0012) in Histologic analysis of kidneys from 3-week-old BHD f/d /KSPCre mice ( Fig. 3 , A -E) revealed marked enlargement due to dilated/cystic tubules and ducts extending from the renal capsule to the tip of the renal papilla, with the largest luminal diameters in the outer medulla. Most of the cells lining the dilated tubules and ducts were hypertrophic with enlarged cytoplasm and nuclei, and many cells were hyperplastic. The subcapsular region of the distorted cortex contained dilated distal convoluted tubules, which were interspersed with morphologically normal proximal tubules, and mildly compressed glomeruli ( Fig. 3, A and B ) . In the medulla and extending into the papilla, the collecting ducts were severely cystic ( Fig. 3, C and D ) . We noted larger hypertrophic cells, particularly in the medulla, with eosinophilic granular cytoplasm and well-defi ned cell borders that frequently protruded into the cystic lumen. The centrally located, round nuclei varied in size from normal, with stippled chromatin and one or more inconspicuous nucleoli, to twice normal size with more euchromatin and a more prominent single nucleolus. An occasional binucleated cell was noted ( Fig. 3, E ) . These "oncocytic-like" cells had some of the features of cells in regions of renal "oncocytosis" found in apparently normal renal parenchyma of BHD patients ( 8 ) . Thin loops of Henle were present in the medulla and showed minimal dilatation. To determine the location of KSP-driven Cre expression, we generated BHD f/d /Rosa26lacZ/KSP-Cre indicator offspring. KSPdriven Cre expression will delete a Neo expression cassette fl anked by loxP sites upstream of the lacZ gene, thereby permitting ␤ -galactosidase expression and its detection by 5-bromo-4-chloro-3-indolyl-D-galactoside (X-Gal) staining in tissue sections. X-Gal staining confi rmed KSP-driven Cre expression in all cells lining the cystic tubules and ducts ( Fig. 3, G ) . KSP-driven Cre expression was also detected in some proximal tubules that were morphologically normal (inset, Fig. 3, G ) .
To classify cystic structures, immunohistochemical analyses were performed on sections from 1-week-old BHD f/d /KSP-Cre kidney sections using DBA [collecting duct marker ( 29 )], NKCC2 [loop of Henle marker ( 30 )], LTA (proximal tubule marker ( 31 )], and thiazide-sensitive Na-Cl-cotransporter [TSC, distal tubule marker ( 32 )] antibodies. Staining patterns in BHD-inactivated kidneys confi rmed the histologic fi ndings that the distal tubules and collecting ducts were dilated ( Fig. 3, H and I ) , whereas the proximal tubules and loops of Henle were relatively normal in appearance ( Fig. 3, H and J ) . Chromophobe renal carcinoma, oncocytoma, and oncocytic hybrid tumors are the most common renal tumors found in BHD patients, and evidence suggests that they arise from intercalated cells ( 33 , 34 ) . Interestingly, strong immunofl uorescence staining for the intercalated cell marker vacuolar-H + -ATPase ( 35 ) was observed in 3-week-old BHD-inactivated kidneys in the numerous hypertrophic cells with oncocytic-like features ( 8 ) that line the dilated ducts ( Fig. 3, K ) .
The increased size and weight of BHD-inactivated kidneys suggested that the cells were hyperproliferating. To evaluate cell proliferation directly, BrdU incorporation into mouse kidneys was measured by immunostaining. More kidney cells from BHD Fig. 4 , A -C). To evaluate proliferating cells in the G2/M phase of the cell cycle, phospho-histone H3 immunostaining was performed on kidney sections. More phospho-histone H3 -stained cells were observed in BHD -inactivated kidney cells than in control littermates ( Fig. 4, D and E ) . Expression of cell cycle -promoting proteins was also analyzed in BHD f/d /KSP-Cre knockout and littermate control kidneys ( Fig. 4, F ) . Expression of cyclin D1, cyclin A, cyclin B1, cdk4, and cdc2 was higher in BHD-inactivated kidneys than in control kidneys, indicating that cells were undergoing rapid proliferation. Cyclin D1 immunohistochemistry revealed strong nuclear staining in dilated tubules of BHD-inactivated kidneys ( Fig. 4, I and J ) but not control kidneys ( Fig. 4, G and H ) , supporting the immunoblotting data that indicated cells lining the dilated tubules were actively proliferating.
To elucidate which signaling pathways were activated by BHD inactivation, protein expression levels of several key molecules in pathways involved in cell growth and proliferation were evaluated by immunoblotting ( Fig. 5, A ) . Phospho-c-Raf (Ser338) levels were elevated in kidney lysates from 3-week-old BHD f/d /KSP-Cre mice compared with controls, suggesting that Raf was activated. Consistent with these data, MEK1/2 and Erk1/2, downstream effectors of Raf signaling, and p90RSK, a downstream effector of Erk1/2, were also highly phosphorylated in BHD-inactivated kidneys. Immunofl uorescence staining of phospho-Erk1/2 in kidney tissue revealed strong specifi c staining of the dilated tubules in BHD-inactivated kidneys ( Fig. 5, D and E ) but minimal restricted staining in the tubules from control littermates ( Fig. 5, B and C ) .
Activation of another major pathway that is frequently activated in cancer, the PI3K-Akt-mTOR pathway ( 36 , 37 ) , was evaluated by immunoblotting ( Fig. 6, A ) . Levels of both total AKT and phospho-Akt (on Thr308) were elevated in BHD-inactivated kidneys compared with control kidneys. mTOR was highly phosphorylated at Ser2448 in BHD-inactivated kidneys, although total mTOR levels were the same for BHD-inactivated and control lysates, consistent with activation of mTOR signaling in BHD-inactivated kidneys. Phosphorylation of a downstream effector of mTOR, S6R, on Ser240/244 was also elevated in BHD-inactivated kidneys. Immunofl uorescence staining for phospho-AKT (Thr 308) revealed membrane staining in some dilated tubules of kidneys in 2-week-old BHD-inactivated mice ( Fig. 6, D and E ) but only restricted staining in kidneys of control mice ( Fig. 6, B and C ) . Phospho-mTOR (Ser2448) staining was seen in all the cells lining the dilated tubules ( Fig. 6, H and I ), whereas phospho-S6R (Ser234/235) staining was seen in only some cells within the dilated tubules ( Fig. 6, L and M ) . Both proteins were expressed at relatively low levels in control kidneys ( Fig. 6, F , G, J, K ).
To determine the biochemical consequences of BHD inactivation on postnatal kidney development, levels of phosphorylated mTOR were evaluated in kidneys of mice aged from P2 to P21 . The staining was identical in control and BHD-inactivated kidneys at P2, with strong staining in the developing cortex ( Fig. 6, N and R ) . After 1 week, phospho-mTOR staining in normal tubules was dramatically decreased in control kidneys ( Fig. 6, O -Q) . However, phospho-mTOR staining was retained in the abnormal dilated tubules from BHD-inactivated kidneys during postnatal development ( Fig. 6, S -U) .
We next asked whether the Akt-mTOR pathway was activated in renal tumors from BHD patients by performing phosphomTOR (Ser2448) immunohistochemistry. Weak to moderate cytoplasmic staining of phospho-mTOR (Ser2448) was observed in one chromophobe and 13 of 15 oncocytic hybrid tumors from four BHD patients with germline mutations (representative images in Fig. 6 , V and W ), whereas almost no signal was detected in four normal kidney samples from one non-BHD and two BHD patients ( Fig. 6, X ) . These results are consistent with those of another report ( 38 ) , which described weak phospho-mTOR (Ser2448) staining in sporadic chromophobe renal cell carcinoma and oncocytoma.
One important question that we sought to clarify was whether or not increased cell proliferation in BHD-targeted kidneys was through a cell-autonomous mechanism or dependent on environment (ie, stroma). To address this question, we performed primary cell culture of isolated tubule cells from BHD-inactivated and control kidneys. BHD-targeted kidney cells grew faster in culture than control kidney cells ( P < .001). Addition of 10 nM rapamycin, which inhibits mTOR , to the culture medium suppressed the rapid growth of BHD -inactivated cells and control cells to the same base level ( Fig. 7, A -E) . The percentage reduction in the growth due to rapamycin treatment by day 9 was twice as large in the BHD-inactivated kidney cells as in the control kidney cells (17.7% vs 9.1%, difference = 8.6%, 95% CI = 5.1% to 12.0%; P < .001).
We also tested whether rapamycin could reverse the cystic kidney phenotype by injecting buffer or rapamycin (2 mg/kg) daily into BHD f/d /KSP-Cre and control mice beginning at P7. Mice were dissected at P21 or before P21, if moribund, and the ratio of kidney to body weight was calculated ( Fig. 7, F ) . Rapamycin treatment did not change the kidney/body weight ratios of control littermates (buffer vs rapamycin: mean = 0.82% vs 0.88%, difference = 0.06%, 95% CI = -0.11% to 0.24%; P = .47), but it reduced the relative kidney/body weight ratio of BHD knockout mice at P21 (buffer vs rapamycin: mean = 12.2% vs 4.64%, difference = 7.6%, 95% CI = 5.2% to 10.0%, P < .001). Kidneys from buffer-treated BHDinactivated mice showed cystic tubules and ducts characteristic of the BHD f/d /KSP-Cre kidney phenotype, with complete disruption of normal anatomic structures ( Fig. 7, G ) . However, kidneys from rapamycin-treated BHD-inactivated mice displayed only mild dilatation of tubules and ducts with retention of some cortical structure at 3 weeks of age ( Fig. 7, H ) .
To examine the effect of rapamycin on survival, BHD f/d /KSPCre mice were divided randomly into two groups (n = 4 and n = 5) and injected with buffer or rapamycin (2 mg/kg per day) daily from P7 until mice were found moribund or died. Rapamycin treatment statistically signifi cantly extended the survival period of BHD f/d / KSP-Cre mice (buffer vs rapamycin, median survival: 23 days vs 41.5 days; P = .0065) ( Fig. 7, I ), although all of these mice eventually died from renal failure.
Discussion
In this article, we describe the development of the first conditional BHD knockout mouse model in which inactivation of the BHD gene is targeted to kidney epithelial cells. Mice with kidney-specific homozygous inactivation of BHD exhibited rapid kidney cell proliferation and progressive dilatation of collecting ducts and distal tubules during the first 3 weeks of life with 100% penetrance, which led to severe kidney dysfunction and death. Increased expression of cell cycle proteins and activation of Raf-Erk1/2 and Akt-mTOR pathways were observed in the BHD knockout kidneys. Heterozygous BHD-targeted littermates displayed a normal phenotype during the study period, suggesting that this dramatic phenotype requires loss of both BHD alleles. We found that treatment with the mTOR inhibitor rapamycin reduced kidney size and the extent of tubule dilatation and prolonged survival of the BHD knockout mice.
We targeted BHD inactivation to the kidney, mainly to the distal nephron, where cadherin 16 is highly expressed (22 ) . However, X-Gal staining of kidneys from mice with the BHD f/d / Rosa26LacZ/KSP-Cre genotype showed mosaic Cre expression in the proximal tubules as well, although the proximal tubules were histologically normal. Only distal tubules and collecting ducts were dilated and cystic in the BHD knockout mice, suggesting that BHD inactivation produces a phenotype specifi cally in the kidney cells that make up the distal nephron, consistent with the fact that human BHD -associated renal tumors -predominantly chromophobe renal carcinomas and renal oncocytic hybrid tumors -arise from the distal nephron ( 8 ) . Furthermore, our immunofl uorescence staining with vacuolar-H + -ATPase suggests that in BHD knockout mice, intercalated cells of the collecting duct may give rise to the hyperplastic cells with oncocytic-like morphology in the dilated tubules, in agreement with several reports suggesting that intercalated cells may be the origin of chromophobe renal cancer and oncocytoma ( 33 , 34 ) . However, although BHD patients have an increased risk for renal cancer, BHD knockout mice developed no signs of renal neoplasia before renal failure at 3 weeks, suggesting that additional genetic or epigenetic events are required for progression to neoplasia.
The Raf-MEK-Erk pathway, which is activated in many cancers and regulates cell proliferation ( 39 ) , was activated in the BHD knockout kidneys, consistent with the increased cyclin D1 expression and cell proliferation we observed. Another important regulator of cell growth and protein synthesis, the PI3K-AKT-mTOR pathway ( 13 ) , was also activated, leading us to hypothesize that a common upstream effector of Raf-MEK-Erk and PI3K-Akt-mTOR pathways (ie, receptor tyrosine kinase) may Actin was used as a control for protein loading and transfer. Data represent typical results for two mice of each genotype from at least three independent experiments. P-S6R(235/236) was used for immunofl uorescence, and P-S6R(240/244) was used for immunoblots ( B -M ) Immuno fl uorescence staining of P-Akt, P-mTOR, and P-S6R (235/236) in kidneys of 2-week-old control and BHD knockout mice. PAkt staining in the control kidney is very restricted ( B , C ). The epithelial cells lining the dilated tubules show membrane staining of P-Akt in BHD knockout mouse kidneys ( D , E ). Note that not all of the dilated tubules were stained. P-mTOR staining was observed in a small population of tubule cells in control mouse kidneys ( F , G ). All dilated tubules in BHD knockout mouse kidneys show mTOR phosphorylation ( H , I ). P-S6R staining in control mouse kidneys shows restricted staining ( J , K ). P-S6R staining in BHD knockout mouse kidneys indicates that mTOR is activated in dilated tubules. 4 ′ -6-Diamidino-2-phenylindole (DAPI) nu clear staining ( blue ) is shown ( L , M ). ( N -U ) P-mTOR staining of kidneys of control and BHD knockout mice at different ages. P-mTOR staining in control ( N ) and BHD knockout kidneys ( R ) shows identical strong staining patterns in the developing cortex at P2. Fewer tubule cells in kidneys of 1-week-old control mice retain P-mTOR staining ( O ). Tubules in BHD knockout mouse kidneys that show dilatation display P-mTOR staining at 1 week (S). At 2 and 3 weeks of age, there are fewer P-mTOR -positive tubules in control mouse kidneys than in BHD knockout mouse kidneys ( P , Q ). All dilated tubules in kidneys of BHD knockout mice at 2 and 3 weeks of age retain P-mTOR staining ( T , U ). ( V -X ) Renal tumors from BHD patients (representative results from 16 immunostained BHD tumor samples) also show P-mTOR staining. P-mTOR staining is seen in the cytoplasm of human BHD patient renal tumor cells ( V , W ). Conversely, very little staining is seen in the normal kidney tissue that is adjacent to tumor 1 ( X ). Representative results from four immunostained normal kidney samples are shown. Scale bar = 20 µ m.
be activated by loss of BHD tumor suppressor function, resulting in cell growth and proliferation within the BHD -null kidney cell. The rapid growth rate of BHD f/d /KSP-Cre tubule cells in primary culture compared with control tubule cells suggests that this cell proliferation is caused by a cell autonomous mechanism. This mechanism is supported by the fact that BHD deletion by KSP-driven Cre recombinase occurred only in kidney epithelial cells, not in stroma, as confi rmed by ␤ -galactosidase staining patterns in BHD f/d /RosaLacZ/KSP-Cre mice. As expected, phospho-mTOR (Ser2448) staining of kidney tubules in the developing neonatal kidney of control littermates was evident at birth but gradually declined during the fi rst 3 weeks of life. However, in BHD knockout mice, inappropriate phospho-mTOR staining was consistently seen in dilated tubules from birth until the mice became moribund at 3 weeks of age, suggesting that BHD is necessary for proper regulation of cell growth and proliferation through Akt-mTOR signaling during postnatal kidney development. Our hypothesis that inappropriate Akt-mTOR signaling may have a major role in the enlarged cystic kidney phenotype is supported by the fact that rapamycin treatment dramatically reduced the kidney size and extent of tubule/duct dilatation, caused complete loss of phospho-S6R staining in tubule cells (data not shown), and extended survival of BHD knockout mice. In a rat model of autosomal polycystic kidney disease (40 ) , rapamycin treatment reduced both the size of the polycystic kidneys and cystic volume and completely restored kidney function through decrease in tubular cell proliferation, which is thought to be the fi rst step in cyst formation. Our study also supports tubule cell hyperproliferation as an initiating event of cystic change and rapamycin inhibition of uncontrolled tubule cell growth both in vitro and in vivo.
However, because rapamycin did not completely reverse the cystic kidney phenotype and the BHD knockout mice eventually died, other signaling pathways (ie, Raf/Erk, Akt) may contribute to the phenotype caused by loss of FLCN function. Because mTOR inhibition by rapamycin reduces negative feedback to IRS1/2 ( 41 ), resulting in Akt activation, the combined treatment of rapamycin and an Akt inhibitor might have a greater effect to suppress uncontrolled cell proliferation in BHD knockout mice. Alternatively, kidney cells that have lost FLCN function before P7 may be irreversibly committed to proliferation before initiation of rapamycin treatment at P7.
We previously reported the identifi cation of a novel FLCN-binding partner, FNIP1, that also interacts with AMPK and suggested that FLCN might interact with the AMPK and mTOR signaling pathways through FNIP1 ( 12 ) . Although in those in vitro studies, which used serum-starved conditions, Akt-mTOR signaling in BHDnull tumor cells was slightly elevated relative to that in BHD-restored cells, no differences were seen in Akt-mTOR signaling between these two cell lines under normal culture conditions. In contrast, mTOR signaling was inappropriately activated in response to kidney-specifi c BHD inactivation in the mouse. The inconsistencies between the BHD-null cell culture data and the BHD knockout mouse phenotype underscore the biologic differences between in vitro and in vivo systems and will require further experimentation for clarifi cation.
The obvious limitation of this study is the use of mice to model human disease. Mouse models of human cancer do not always recapitulate the human cancer phenotype, as is also the case for the BHD knockout mouse model. Although we have succeeded in inactivating both copies of the BHD gene in mouse kidney epithelial cells, the highly cystic kidneys did not develop frank renal neoplasms before renal failure and death. Inactivation of both BHD alleles in a human BHD patient kidney cell leads to renal tumorigenesis, but additional unknown genetic events (not introduced in the BHD knockout mouse) may occur for kidney tumor development and progression. We were encouraged by the partial response to rapamycin treatment seen in the BHD knockout mice but cannot rule out the possibility that other pathways may have been affected by BHD inactivation and that the BHD knockout mouse may be more effectively treated by combination drug therapy.
In conclusion, we have developed a kidney-specifi c BHDtargeted mouse model that displays a marked polycystic phenotype within the fi rst 3 weeks of life. In this model, homozygous inactivation of BHD results in abrupt, uncontrolled cell proliferation, supporting the idea that loss of BHD tumor suppressor function may be the fi rst event in multistep renal carcinogenesis in the mouse ( 42 , 43 ) . For the BHD-inactivated mouse kidney cell to progress to a neoplasm, we hypothesize that additional genetic or epigenetic events may be required to give the BHD-null cell a growth advantage and to facilitate progression to renal carcinoma. Indeed, multistep renal cancer progression is suggested by the presence of regions of benign "oncocytosis" adjacent to oncocytic-hybrid tumors in the kidneys of BHD patients ( 8 ) . Because BHD-targeted mice develop a striking kidney phenotype over a very short time, this model may be useful for the development and testing of new therapies or drugs (eg, rapamycin) with which to treat BHD patients and BHD-associated kidney cancers, including sporadic chromophobe renal cancer.
